A compound of formula wherein L is absent or is methylene or ethylene; A is CH and Y is N; or A is CH and Y is CH; or A is N and Y is CH; R 1 is selected from the group consisting of: C 1-6 alkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo, C 3-6 cycloalkyl and OC 3-6 cycloalkyl; phenyl optionally substituted with 1 to 3 groups independently selected from the group consisting of CF 3, halo, C 3-6 cycloalkyl, OC 3-6 cycloalkyl, OC 1-6 alkyl optionally substituted with one to three halo; and C 3-6 cycloalkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo and C 1-6 alkyl optionally substituted with 1 to 3 halo; R 2 is selected from the group consisting of H, C 1-6 alkyl, OCF 3, C 3-6 cycloalkyl, OC 1-6 alkyl, OC 3-6 cycloal kyl; R 3 is selected from the group consisting of H, C 1-6 alkyl, C 3-6 cycloalkyl, OC 3-6 cycloalkyl; wherein each of the C 1-6 alkyl, C 3-6 cycloalkyl, OC 3-6 cycloalkyl of the R 3 group may be optionally substituted with one to three groups each independently selected from the group consisting of halo, OH, OC 1-6 alkyl, SC 1-6 alkyl, N(C 1-6 alky) 2; and wherein one to three carbon atoms of the C 1-6 alkyl of the R 3 group may optionally be replaced one or two moieties selected from the group consisting of NH, N(C 1-6 alkyl), O, and S; R 4 and R 5 are each independently selected from the group consisting of H or C 1-6 alkyl; R 3 and R 4 can together with the atom to which they are attached join to form a 3 to 9-membered carbocyclyl ring which optionally may contain one to three heteroatoms selected from the group consisting of N, O, and S; or R 3 and R 5 can together form a 3 to 9-membered bicyclic ring which optionally may contain one to three heteroatoms selected from the group consisting of N, O, and S; R 6 is selected from the group consisting of H, C 1-6 alkyl, CN, CF 3, OCF 3, C 3-6 cycloalkyl, OC 1-6 alkyl, and OC 3-6 cycloalkyl; and R 7 is selected from the group consisting of H and OC 1-6 alkyl; or a pharmaceutically acceptable salt thereof. L is absent or is methylene or ethylene; A is CH and Y is N; or A is CH and Y is CH; or A is N and Y is CH; R 1 is selected from the group consisting of: C 1-6 alkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo, C 3-6 cycloalkyl and OC 3-6 cycloalkyl; phenyl optionally substituted with 1 to 3 groups independently selected from the group consisting of CF 3, halo, C 3-6 cycloalkyl, OC 3-6 cycloalkyl, OC 1-6 alkyl optionally substituted with one to three halo; and C 3-6 cycloalkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo and C 1-6 alkyl optionally substituted with 1 to 3 halo; C 1-6 alkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo, C 3-6 cycloalkyl and OC 3-6 cycloalkyl; phenyl optionally substituted with 1 to 3 groups independently selected from the group consisting of CF 3, halo, C 3-6 cycloalkyl, OC 3-6 cycloalkyl, OC 1-6 alkyl optionally substituted with one to three halo; and C 3-6 cycloalkyl optionally substituted with 1 to 3 groups independently selected from the group consisting of halo and C 1-6 alkyl optionally substituted with 1 to 3 halo; R 2 is selected from the group consisting of H, C 1-6 alkyl, OCF 3, C 3-6 cycloalkyl, OC 1-6 alkyl, OC 3-6 cycloal kyl; R 3 is selected from the group consisting of H, C 1-6 alkyl, C 3-6 cycloalkyl, OC 3-6 cycloalkyl; wherein each of the C 1-6 alkyl, C 3-6 cycloalkyl, OC 3-6 cycloalkyl of the R 3 group may be optionally substituted with one to three groups each independently selected from the group consisting of halo, OH, OC 1-6 alkyl, SC 1-6 alkyl, N(C 1-6 alky) 2; and wherein one to three carbon atoms of the C 1-6 alkyl of the R 3 group may optionally be replaced one or two moieties selected from the group consisting of NH, N(C 1-6 alkyl), O, and S; R 4 and R 5 are each independently selected from the group consisting of H or C 1-6 alkyl; R 3 and R 4 can together with the atom to which they are attached join to form a 3 to 9-membered carbocyclyl ring which optionally may contain one to three heteroatoms selected from the group consisting of N, O, and S; or R 3 and R 5 can together form a 3 to 9-membered bicyclic ring which optionally may contain one to three heteroatoms selected from the group consisting of N, O, and S; R 6 is selected from the group consisting of H, C 1-6 alkyl, CN, CF 3, OCF 3, C 3-6 cycloalkyl, OC 1-6 alkyl, and OC 3-6 cycloalkyl; and R 7 is selected from the group consisting of H and OC 1-6 alkyl; or a pharmaceutically acceptable salt thereof.